Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News vTv Therapeutics Inc VTVT

Healthcare Biotechnology
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VTVT)

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

PR Newswire March 19, 2024

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

GlobeNewswire March 13, 2024

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

GlobeNewswire March 4, 2024

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

GlobeNewswire March 1, 2024

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

GlobeNewswire February 28, 2024

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

PR Newswire February 22, 2024

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2023

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

GlobeNewswire November 8, 2023

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

GlobeNewswire November 2, 2023
View More News ››

Opinion & Analysis (NDAQ:VTVT)

vTv Therapeutics' Shares open 80% Higher on Phase 2 Type 1 Diabetes Trial Data

Streetwise Reports February 11, 2020
View More Opinion ››

Bullboard Posts (NDAQ:VTVT)

vTv Therapeutics Announces $51 Million Private Placement fro

BREAKING NEWS: $VTVT vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the...
whytestocks - February 28, 2024

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exc

NEWS: $VTVT vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown...
whytestocks - June 16, 2023

still holding this stock

for over a year,there was big buying by insiders all of last year,and this is a long term hold for me, which is about a year in my terms...
coolfooldumbguy - February 10, 2020

still holding this stock

it is starting to pick up.so glta.
coolfooldumbguy - January 2, 2019

coming year should be good for me

with this stock bought it last week,so glta.
coolfooldumbguy - December 31, 2018

RE:bought this morning at

A few months back I bought it at $1.92 just before they announced their Phase 3 failed. Sold it at $1.22 and bought CRMD at 58 cents...
Pandora - December 28, 2018
View more Bullboard ››

Etruscus Resources Corp.

Etruscus Resources Corp.

Etruscus Resources is a precious and critical metals exploration company focused on the development of two properties that ...
View More »